1. Home
  2. ARVN vs DGICB Comparison

ARVN vs DGICB Comparison

Compare ARVN & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.95

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

DGICB

Donegal Group Inc. Class B

HOLD

Current Price

$19.15

Market Cap

654.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
DGICB
Founded
2015
1986
Country
United States
United States
Employees
N/A
851
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
654.6M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
DGICB
Price
$8.95
$19.15
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$15.05
N/A
AVG Volume (30 Days)
858.9K
473.0
Earning Date
05-04-2026
04-30-2026
Dividend Yield
N/A
3.34%
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
$2.26
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.06
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$13.84
52 Week High
$14.22
$20.30

Technical Indicators

Market Signals
Indicator
ARVN
DGICB
Relative Strength Index (RSI) 37.05 53.75
Support Level $8.72 $15.35
Resistance Level $10.18 $19.90
Average True Range (ATR) 0.47 0.36
MACD 0.00 -0.08
Stochastic Oscillator 28.82 76.84

Price Performance

Historical Comparison
ARVN
DGICB

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

Share on Social Networks: